Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Completed
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
07/01/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have untreated acute lymphoblastic leukemia.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/01/2016
Locations: University of Illinois at Chicago Health Sciences Center, Chicago, Illinois +2 locations
Conditions: Leukemia
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide and filgrastim in treating patients with stage IV, relapsed, or refractory low-grade follicular non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/30/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Lymphoma
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Unknown
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2016
Locations: Rush University Medical Center, Chicago, Illinois +6 locations
Conditions: Invasive Breast Cancer
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/19/2016
Locations: University of Chicago Cancer Research Center, Chicago, Illinois +3 locations
Conditions: Leukemia
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Completed
This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/15/2016
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Lupus Nephritis, Lupus Erythematosus, Systemic
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS)... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/18/2015
Locations: Children's Memorial Hospital - Chicago, Chicago, Illinois
Conditions: Central Nervous System Tumor, Pediatric
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
Terminated
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/02/2015
Locations: University of Illinois at Chicago, Chicago, Illinois +1 locations
Conditions: Melanoma (Skin)
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Completed
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2015
Locations: Southern Illinois Hematology/Oncology, Centralia, Illinois +2 locations
Conditions: Non-small Cell Lung Cancer
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and radiation therapy and kill more cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma. PURPOSE: Randomized phase III tri... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/05/2015
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois +4 locations
Conditions: Multiple Myeloma
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known if combination chemotherapy is more effective with or without thalidomide for multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without thalidomide in treating patients who have refractory multiple myeloma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: MBCCOP - University of Illinois at Chicago, Chicago, Illinois +3 locations
Conditions: Multiple Myeloma
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This phase II trial studies how well giving imatinib mesylate together with chemotherapy and peripheral stem cell transplantation works in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Giving imatinib mesylate together with chemotherapy and peripheral ste... Read More
Gender:
ALL
Ages:
Between 15 years and 59 years
Trial Updated:
11/13/2014
Locations: Saint Joseph Medical Center, Bloomington, Illinois +25 locations
Conditions: Adult Acute Lymphoblastic Leukemia in Remission